Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (Nasdaq: CLDI) is a clinical-stage biopharmaceutical company focused on oncolytic virus-based cell therapies for oncology indications. The company reached the public markets through its merger with First Light Acquisition Group (FLAG), a blank-check company that completed its SPAC IPO in 2021 and was sponsored by First Light Capital Group. The combination targeted the cell and gene therapy segment of the broader healthcare and life sciences sector. Calidi filed this Form 10-Q with the SEC on November 14, 2022, under accession number 0001193125-22-282874, reflecting the company's ongoing compliance reporting obligations during the de-SPAC process. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal-stage analytics on CLDI and hundreds of other SPAC transactions.